Patents Assigned to Innate Pharma S.A.S.
-
Patent number: 10253095Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.Type: GrantFiled: July 15, 2011Date of Patent: April 9, 2019Assignees: INNATE PHARMA S.A.S., NOVO NORDISK A/SInventors: Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
-
Patent number: 9333255Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: GrantFiled: October 1, 2013Date of Patent: May 10, 2016Assignees: Innate Pharma S.A.S., Novo Norkisk A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
-
Patent number: 9018366Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 18, 2013Date of Patent: April 28, 2015Assignees: Innate Pharma S.A.S, Novo Nordisk A/SInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Publication number: 20140023646Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: ApplicationFiled: October 1, 2013Publication date: January 23, 2014Applicants: Innate Pharma S.A.S., Novo Norkisk A/SInventors: Peter Andreas, Nicolai, Reumert WAGTMANN, Francois ROMAGNE, Joakim GLAMANN
-
Patent number: 8614307Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: January 11, 2012Date of Patent: December 24, 2013Assignees: Novo-Nordisk A/S—Novo Alle, Innate Pharma S.A.S.Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurant Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkjaer, Kristian Kjaergaard, Petrus Johannes Loius Spee, Milchael Wilken
-
Patent number: 8551483Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: GrantFiled: January 6, 2006Date of Patent: October 8, 2013Assignees: Innate Pharma S.A.S., Novo Nordisk A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
-
Publication number: 20130143269Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: January 18, 2013Publication date: June 6, 2013Applicants: INNATE PHARMA S.A.S, NOVO-NORDISK A/S - NOVO ALLÉInventors: Novo-Nordisk A/S - Novo Allé, Innate Pharma S.A.S
-
Patent number: 8388970Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: October 2, 2008Date of Patent: March 5, 2013Assignees: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Publication number: 20110293561Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.Type: ApplicationFiled: July 15, 2011Publication date: December 1, 2011Applicants: INNATE PHARMA S.A.S., NOVO NORDISK A/SInventors: FRANCOIS ROMAGNÉ, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
-
Publication number: 20090196850Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.Type: ApplicationFiled: January 6, 2006Publication date: August 6, 2009Applicants: NOVO NORDISK A/S, INNATE PHARMA S.A.S.Inventors: Francois Romagne, Peter Andreas Nicolai Reu Wagtmann, Joakim Glamann
-
Patent number: 7517966Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.Type: GrantFiled: May 25, 2005Date of Patent: April 14, 2009Assignees: Innate Pharma S.A.S., Universita Di GenovaInventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
-
Publication number: 20090075340Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: October 2, 2008Publication date: March 19, 2009Applicants: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Soren Berg Padkaer, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjaergaard, Anders Svensson
-
Publication number: 20090035305Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: ApplicationFiled: January 6, 2006Publication date: February 5, 2009Applicants: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Peter Andreas Wagtmann, Francois Romagne, Joakim Glamann
-
Publication number: 20080305117Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: January 6, 2006Publication date: December 11, 2008Applicants: Novo Nordisk A/S/, Innate Pharma S.A.S.Inventors: Soren Berg Padkaer, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjaergaard
-
Publication number: 20080063717Abstract: The present invention relates to pharmaceutical compositions having an effect on the proliferation of NK cells, to a method for specifically stimulating the proliferation of NK cell and to the use of same in the manufacture of a drug for the antitumoral prevention, palliation, and therapy of e.g., melanoma, hepatocarcinoma or lung adenocarcinoma and for anti-microbial prevention, palliation and therapy.Type: ApplicationFiled: December 22, 2003Publication date: March 13, 2008Applicant: Innate Pharma, S.A.S.Inventors: Francois Romagne, Andre Pascale
-
Publication number: 20060194755Abstract: The present invention relates to compositions and methods for regulating an immune response in a subject, particularly to treat a subject with a tumor, notably a solid tumor, or an infectious disease. Disclosed are methods of regulating the innate immunity in a subject, such as by regulating the activity of ?? T cells in a subject. Disclosed are combinations of particular agents, such as a cytokine and a ?? T cell activator, particular regimens and dosages can produce a remarkable expansion of ?? T cells in vivo and a remarkable increase in a subject's immune defense. The invention can be used for therapeutic purposes, to produce, regulate or facilitate an immune response in a subject.Type: ApplicationFiled: December 2, 2003Publication date: August 31, 2006Applicant: Innate Pharma, S.A.S.Inventors: Francois Romagne, Helene Sicard, Jerome Tiollier
-
Patent number: 6979546Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.Type: GrantFiled: January 7, 2002Date of Patent: December 27, 2005Assignees: Universita di Genova, Innate Pharma S.A.S.Inventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni